



Novo Nordisk Standardizes on Veeva Vault RIM to Transform Regulatory Affairs

Agile approach accelerates rollout and business value

For Novo Nordisk, the need to replace aging technologies created an opportunity to transform regulatory affairs. The top pharmaceutical company, which supplies nearly half the world's insulin, had a disparate mix of large, highly customized systems, minor homegrown tools, and tracking spreadsheets. Their goal was to create a more connected IT environment while also streamlining regulatory operations, and they chose the Veeva Vault RIM platform to help get them there.

NOVO NORDISK – AT A GLANCE

- Corporate Headquarters: Bagsværd, Denmark
- Employees: 43,000+
- Primary Therapeutic Area: Diabetes, metabolic diseases, and rare blood disorders

Shortening Implementation Time

Novo Nordisk began its agile Vault RIM deployment program in 2019, and is on track to complete the project one year earlier than would have been possible using a traditional waterfall approach. Their rollout strategy includes the development of minimum viable products (MVPs) and automated validations for the most critical configurations to further optimize efforts. These MVPs are a valuable interim step on the road to final go-live as early users test new ways of working and provide feedback. In addition, Novo Nordisk's IT team and dedicated LoB subject matter experts gain experience configuring and releasing Vault RIM across the organization.

Improving Efficiency by Exiting Legacy Systems

Novo Nordisk will usher in a new era of simplified submissions management when Vault Submissions and Vault Submissions Archive launch globally. The move will reduce the administrative burden on regulatory professionals and allow IT to retire legacy systems, which are costly and time-consuming to maintain. The organization plans to replicate its success with MVPs and agile delivery methods when implementing Vault Registrations, which is slated to go live in 2021.

“We're going to set the digital transformation pace for Regulatory Affairs.”

– Lars Westergaard Luxhøj, Project Director, Novo Nordisk